0000000000230889

AUTHOR

Masafumi Ikeda

showing 5 related works from this author

Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

2019

Sorafenibmedicine.medical_specialtyElevated alpha-fetoproteinbusiness.industryHematologymedicine.diseaseGastroenterologyRamucirumabInterval dataOncologyInternal medicineHepatocellular carcinomaMedicineIn patientProgression-free survivalbusinessExposure responsemedicine.drugAnnals of Oncology
researchProduct

79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary trac…

2020

Cisplatinmedicine.medical_specialtyBiliary tract cancerbusiness.industryPlacebo-controlled studyHematologyGastroenterologyGemcitabineFirst line treatmentOncologyInternal medicinemedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase I…

2020

549 Background: Intermediate-stage HCC, as defined as Barcelona Clinic Liver Cancer (BCLC) Stage B, is a heterogeneous disease in terms of liver function and tumor load. REACH (NCT01140347) and REACH-2 (NCT02435433) investigated ramucirumab (RAM) in patients (pts) with HCC after prior sorafenib (SOR), with REACH-2 enrolling only pts with baseline AFP ≥400 ng/mL. An exploratory analysis of outcomes by BCLC stage was performed. Methods: All pts had HCC (BCLC stage C or B disease refractory/not amenable to locoregional therapy), Child-Pugh A, ECOG PS 0-1, and prior SOR. Pts were randomized to RAM 8 mg/kg or Placebo (P) Q2W. A pooled meta-analysis of independent pt data (stratified by study) f…

Cancer Researchmedicine.medical_specialtyElevated alpha-fetoproteinbusiness.industrymedicine.diseaseGastroenterologyIntermediate stageRamucirumab03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisHepatocellular carcinomaInternal medicinemedicineLiver functionStage (cooking)Liver cancerbusinessTumor Load030215 immunologyJournal of Clinical Oncology
researchProduct

P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

2021

CisplatinFirst line treatmentBiliary tract cancerOncologybusiness.industrymedicineCancer researchHematologybusinessGemcitabinemedicine.drugAnnals of Oncology
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct